AstraZeneca pauses £200m investment in Cambridge research site | AstraZeneca

Drug producer Astrazeneca paused the investment of 200 million pounds to the Cambridge research site and completed a depressing week for the UK pharmaceutical industry.

The decision of the biggest company in the UK, none Too many £ 650 million investment package in the UK – initially announced in March 2024 – currently continues.

Now the Cambridge project of £ 200 million would create 1,000 jobs. In January, Astrazeneca planned to invest £ 450 million in the vaccine production facility in Merseyside and a deduction with the British government support.

An Astrazerca Spokesman: uz We are constantly re -evaluating our company’s investment needs and we can confirm that our expansion in Cambridge pauses. We have no other interpretation to make. ”

The latest decline in England contrasts with its moves in Astrazeneca’s other judicial regions. In July, the company announced that Donald Trump will invest in the United States by 2030 (£ 37 billion) by 2030 as part of commitments as a threat to the sector -specific tariffs to the sector.

Headquartered in Cambridge, the British drug producer, the US investment will finance a new drug production facility in Virginia, and Maryland, Massachusetts, California and Texas will expand the production of research and development and cell therapy.

News from Astrazeneca limits one -week negative announcements and warnings from an important UK industry.

Keir Starmer government described the life sciences as “one of the crown jewels of the UK economy ,, while the previous conservative government promised to translate the country In a “Global Science and Technology Super Power” until 2030.

Nevertheless, on Wednesday, US drug producer Merck dismissed 125 scientists in the capital this year as well as 1 billion pounds London Research Center.

The new laboratory planned called the UK Discovery Center Belgrade House Site In the face of St Pancras and King’s Cross stations, it was already under construction and was planned to be opened for two years. Finally, he was expected to employ approximately 800 people, including 180 scientists.

Meanwhile, a leading scientist at Oxford University and former Reggius Medical Professor Sir John Bell warned that other major pharmaceutical companies would stop investing in England on Thursday.

BBC Radio 4 said that in the last six months, large pharmaceutical companies have spoken to several chief executives and they will not all invest in the same area and in the UK any more. ”

Later on Friday, Paul Naish, President of Market Access to the French pharmaceutical company of England, said that Guardian Britain has become a “good place to develop or sell drugs, and called for a“ Treasury from the Treasury ”for life sciences.